TransMedics Group saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 69 to 74.
Can You Really Time The Stock Market?
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks compares to other publicly traded companies.
History reveals that the top-performing stocks typically have an 80 or better RS Rating in the early stages of their moves. See if TransMedics Group can continue to rebound and hit that benchmark.
TransMedics Group has moved more than 5% past a 92.63 entry in a first-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
While the company's top line growth fell last quarter from 50% to 48%, EPS grew 100%, up from 58% in the prior report. Keep an eye out for the company's next round of numbers on or around Jul. 30.
The company earns the No. 13 rank among its peers in the Medical-Products industry group. Hinge Health, Boston Scientific and Insulet are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
